<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4166">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622332</url>
  </required_header>
  <id_info>
    <org_study_id>SIR365-US-101</org_study_id>
    <nct_id>NCT04622332</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sironax USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sironax USA, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      • To evaluate overall safety and tolerability of SIR1-365 in patients with severe COVID-19&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess the clinical efficacy of SIR1-365 in patients with severe COVID-19&#xD;
&#xD;
        -  To assess the effects of SIR1-365 on multiple inflammatory biomarker levels including&#xD;
           C-reactive protein (CRP), ferritin, lymphocyte and neutrophil counts, cytokines, and&#xD;
           chemokines&#xD;
&#xD;
        -  To assess the effects of SIR1-365 on biomarkers indicative of target engagement in&#xD;
           patients with severe COVID-19&#xD;
&#xD;
        -  To assess the effects of SIR1-365 on biomarkers indicative of kidney injury in patients&#xD;
           with severe COVID-19&#xD;
&#xD;
        -  To assess the effects of SIR1-365 on biomarkers indicative of cardiovascular endothelial&#xD;
           cell damage in patients with severe COVID-19&#xD;
&#xD;
        -  To characterize plasma pharmacokinetics (PK) of SIR1-365 in patients with severe&#xD;
           COVID-19&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant is approximately 28 days including a 14-day treatment period&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with any TEAEs during the treatment period</measure>
    <time_frame>Baseline to Day 14</time_frame>
    <description>Primary Safety Endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with any AEs, SAEs and drug-related AEs during the study</measure>
    <time_frame>Baseline to Day 14 and Day 28</time_frame>
    <description>Secondary Safety Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinically significant abnormality in clinical laboratory tests and ECG during the study</measure>
    <time_frame>Baseline to Day 14 and Day 28</time_frame>
    <description>Secondary Safety Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 7 and Day 14 in PaO2/FiO2 ratio</measure>
    <time_frame>Baseline to Day 7 and Day 14</time_frame>
    <description>Clinical Efficacy Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement of oxygenation defined as oxygen saturation (pulse oximetry) &gt;93% and increased ≥1% from Baseline breathing only room air in the 48 hours preceding the measurement during the study</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Clinical Efficacy Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days without oxygen use during the study</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Clinical Efficacy Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical improvement defined as a reduction of 2 points in the WHO ordinal scale during the study</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Clinical Efficacy Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days hospitalized during the study</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Clinical Efficacy Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients free of respiratory failure during the study</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Clinical Efficacy Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality rate during the study</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Clinical Efficacy Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 7 and to Day 14 in plasma CRP level</measure>
    <time_frame>Baseline to Day 7 and to Day 14</time_frame>
    <description>Inflammatory Biomarker Measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach 50% reduction from Baseline in plasma CRP level during the treatment period</measure>
    <time_frame>Baseline to Day 14</time_frame>
    <description>Inflammatory Biomarker Measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of the patients to reach 50% reduction from Baseline in plasma CRP level during the treatment period</measure>
    <time_frame>Baseline to Day 14</time_frame>
    <description>Inflammatory Biomarker Measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 7 and Day 14 in serum cytokine levels</measure>
    <time_frame>Baseline to Day 7 and Day 14</time_frame>
    <description>Inflammatory Biomarker Measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 7 and Day 14 in plasma pRIP1 and pMLKL levels</measure>
    <time_frame>Baseline to Day 7 and Day 14</time_frame>
    <description>Biomarker Assessment for Target Engagement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 7 and Day 14 in urine NGAL and KIM-1 levels</measure>
    <time_frame>Baseline to Day 7 and Day 14</time_frame>
    <description>Biomarker Assessment for Kidney Injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma drug levels</measure>
    <time_frame>Baseline to Day 7 and Day 14</time_frame>
    <description>Assessment of PK profile</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>SIR1-365</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SIR1-365 dose 1 daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo dose 1 daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SIR1-365</intervention_name>
    <description>Route of administration: oral</description>
    <arm_group_label>SIR1-365</arm_group_label>
    <other_name>Pharmaceutical form: tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Route of administration: oral</description>
    <arm_group_label>Matching placebo</arm_group_label>
    <other_name>Pharmaceutical form: tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized patient with clinical diagnosis of SARS-CoV-2 virus infection per World&#xD;
             Health Organization criteria including positive nucleic acid test of any specimen&#xD;
             (e.g., respiratory, blood, or other bodily fluid) within 2 weeks prior to screening.&#xD;
&#xD;
          -  Symptoms suggestive of severe systemic illness with COVID-19, which could include any&#xD;
             of the following symptoms: fever, cough, sore throat, malaise, headache, muscle pain,&#xD;
             gastrointestinal symptoms, or shortness of breath at rest, or respiratory distress.&#xD;
&#xD;
          -  Clinical signs indicative of severe systemic illness with COVID-19, which could&#xD;
             include any of the following clinical signs: respiratory rate ≥ 30 per minutes, heart&#xD;
             rate ≥ 125 per minute, SpO2 ≤ 93% on room air, or PaO2/FiO2 ratio &lt; 300 mmHg.&#xD;
&#xD;
          -  Men or women ≥18 but ≤80 years of age at the time of signing the informed consent.&#xD;
&#xD;
          -  Patient is able to understand the purpose and risks of the study and provide signed&#xD;
             and dated informed consent or have a legal representative provide consent and&#xD;
             authorization to use protected health information (in accordance with national and&#xD;
             local patient privacy regulations).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient requires endotracheal intubation and mechanical ventilation, oxygen delivered&#xD;
             by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal&#xD;
             cannula at flow rates &gt;20 L/min with fraction of delivered oxygen ≥ 0.5), noninvasive&#xD;
             positive pressure ventilation, extracorporeal membrane oxygenation (ECMO), or clinical&#xD;
             diagnosis of respiratory failure.&#xD;
&#xD;
          -  Patient with shock defined by systolic blood pressure &lt; 90 mm Hg, or diastolic blood&#xD;
             pressure &lt; 60 mm Hg or requiring vasopressor.&#xD;
&#xD;
          -  Patient with multi-organ dysfunction or failure defined by an increase in the&#xD;
             Sequential Organ Failure Assessment score of 2 points or more.&#xD;
&#xD;
          -  Patient is unlikely to survive beyond 2 days at the discretion of Investigator.&#xD;
&#xD;
          -  Patient has used chronic systemic corticosteroids within 2 weeks prior to screening.&#xD;
&#xD;
          -  Patient with positive results for human immunodeficiency virus (HIV) or hepatitis B or&#xD;
             C test.&#xD;
&#xD;
          -  Patient has known active tuberculosis (TB), history of uncontrolled TB, suspected or&#xD;
             known systemic bacterial or fungal infections within 4 weeks prior to screening.&#xD;
&#xD;
          -  Patient has any other condition, which makes the patient unsuitable for study&#xD;
             participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Li, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sironax USA, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simon Li, MD, PhD</last_name>
    <phone>609-651-1425</phone>
    <email>simon.li@sironax.com</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

